Rosen Tantau Mathias Tantau Nachfolger
Tornescher Weg 13
Hans Evers, Rosen Tantau Mathias Tantau Nachfolger, Uetersen, Germany
|Agent in Canada:||
336 MacLaren Street
Tel: 613-238-6404 ext. 223
|Grant of Rights Date:||2006-06-01|
|Date rights revoked:||2011-10-17|
"TANotika' is a bedding rose variety which has a narrow bushy growth habit, low plant height and medium width. The young shoot has a very weak to weak anthocyanin colouration which gives it a bronze to reddish brown hue. The stem has absent to very few number of short prickles and a medium number of long prickles which are concave in shape. The leaves are medium green in colour and have medium glossiness on the upper side. The leaflet in cross section is flat and has a weak undulation of the margin. The terminal leaflet has a medium length and width with a base that is wedge shaped.
'TANotika' flowers mid-season and flowers almost continuously. There are a medium number of flowers per flowering shoot and the flower pedicel has a very low number of hairs or prickles. The flower bud is ovate and sepal extensions are moderate. The flower is irregularly rounded when viewed from above, flat on the upper part when viewed from the side and concave on the lower part when viewed from the side. The flower is a double type with medium to many number of petals that are medium in length and width. 'TANotika' has medium to large greenish white (RHS 155C) flowers. The petals have a small sized yellow-green spot at the base of the inner side. The petal margin has strong reflexing and weak undulation. The outer stamen has a yellow filament. 'TANotika' has a weak fragrance.
Origin & Breeding History: 'TANotika' originated from the cross between an unnamed white hybrid tea seedling and an unnamed large flowered white seedling in 1994 at Uetersen, Germany.
Tests & Trials: The detailed description is based on the UPOV report of Technical Examination, CPVO reference number 1997/0259, application number ROO 2548, grant number 4868, purchased from the CPVO, Angers, France. The trials were conducted in Wageningen, The Netherlands in 1998.
- Date modified: